Clinical Oncology
Volume 22, Issue 6 , Pages 438-447 , August 2010

Management of Differentiated Thyroid Cancer with Rising Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scan

  • M. Chao

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: M. Chao, Department of Nuclear Medicine, Affiliated Hospital of Medical College Qingdao University, Qingdao, China.

Received 4 February 2010 ,Accepted 3 May 2010.

References 

  1. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. 1994;79:98–105
  2. Pacini F, Pinchera A. Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Biochimie. 1999;81:463–467
  3. Chao M, Anren K, Jiawei X, Tiekun M. The possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scan. J Nucl Med. 2005;46:1473–1480
  4. Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:1519–1525
  5. Chao M, Kuang AR. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev. 2009;1:CD006988
  6. Koh JM, Kim ES, Ryu JS, et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol. 2003;58:421–427
  7. Pacini L, Agate R, Elisei M. Outcome of differentiated thyroid cancer with detectable serum Tg and negative 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092–4097
  8. Tian R, Pan M, Kuang A. Evaluation of 131I therapy for differentiated thyroid carcinoma patients with elevated Tg and negative 131I whole body scan. Chin J Nucl Med. 2003;23:27–28
  9. De Keizer B, Koppeschaar HP, Zelissen PM, et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med. 2001;28:198–202
  10. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488–1492
  11. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463
  12. Van Tol KM, Jager PL, De Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol. 2003;148:589–596
  13. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888–1891
  14. Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imag. 2004;31:1500–1504
  15. Fatourechi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521–1526
  16. Pachucki J, Burmeister LA. Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur J Endocrinol. 1997;137:254–261
  17. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?. J Nucl Med. 1990;31:1766–1771
  18. Schaap J, Eustatia-Rutten CF, Stokkel M, et al. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?. Clin Endocrinol (Oxf). 2002;57:117–124
  19. Rosário PW, Maia FC, Barroso AL, Purisch S. [Investigating patients with differentiated thyroid carcinoma and elevated serum thyroglobulin but negative whole-body scan], Arq Bras Endocrinol Metabol. 2005;49:246–252
  20. Saghari M, Gholamrezanezhad A, Mirpour S, et al. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nucl Med Commun. 2006;27:567–572
  21. Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqi S, Abdal Salam S, Shoukri M. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest. 2005;28:540–546
  22. Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R. Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course. Rev Esp Med Nucl. 2007;26:138–145
  23. Pace L, Klain M, Albanese C, et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imag. 2006;33:179–183
  24. Zanotti-Fregonara P, Keller I, Rubello D, Calzada-Nocaudie M, Devaux JY, Hindié E. Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans. J Endocrinol Invest. 2009;32:267–271
  25. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896–1900
  26. Ma Chao, Xie Jiawei, Kuang Anren. Is blind 131I therapy justified for patients with negative Tg and positive 131I WBS?. J Nucl Med. 2005;46:1164–1170
  27. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  28. Schlumberger M, Pacini F, Wiersinga WM, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol. 2004;151:539–548
  29. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306
  30. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 1988;29:1790–1794
  31. Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. 1994;79:98–105
  32. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab. 2000;85:175–178
  33. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499–1501
  34. Robbins RJ, Chon JT, Fleisher M, Larson S, Tuttle RM. Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to monitor for residual thyroid carcinoma?. J Clin Endocrinol Metab. 2002;87:3242–3247
  35. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–3885
  36. David A, Blotta A, Bondanelli M, et al. Serum thyroglobulin concentrations and (131)I whole body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med. 2001;42:1470–1475
  37. Vitale G, Lupoli GA, Ciccarelli A, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf). 2002;56:247–252
  38. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J Clin Endocrinol Metab. 2002;87:1490–1498
  39. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002;12:37–43
  40. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5686–5690
  41. Wartofsky L. Management of low risk well differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-stimulated thyroglobulin Study Group. Thyroid. 2002;12:121–134
  42. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imag. 2007;34:487–495
  43. Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol. 2009;70:17–24
  44. van Tol KM, Jager PL, Piers DA, et al. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid. 2002;12:381–387
  45. Dong MJ, Liu ZF, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun. 2009;30:639–650
  46. Petrich T, Börner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imag. 2002;29:641–647
  47. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:91–95
  48. Grunwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547–1552
  49. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxyglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–2302
  50. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin N Am. 1990;19:741–760
  51. Mazzaferri EL. Management of differentiated thyriod carcinoma patients with negative whole-body radioiodine scans and elevated serum thyroglobulin levels. In:  Mazzaferri EL,  Harmer C,  Mallick UK,  Kendall-Taylor P editor. Practical management of thyroid cancer – A multidisciplinary approach. London: Springer-Verlag; 2006;[Chapter 20]
  52. Cooper DS, Doherty GM, Haughen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214
  53. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab. 2010;95:1169–1173
  54. Mallick UK, Charalambous H. Current issues in the management of differentiated thyroid cancer. Nucl Med Commun. 2004;25:873–881
  55. Schlumberger M, Chougnet C, Brassard M, Leboulleux S, Baudin E. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol. 2010;22:448–455
  56. Mallick UK. Thyroid cancer: evidence-based optimal management and the search for a cure. Clin Oncol. 2010;22:394

PII: S0936-6555(10)00175-5

doi: 10.1016/j.clon.2010.05.005

Clinical Oncology
Volume 22, Issue 6 , Pages 438-447 , August 2010

Article Tools

* Image Usage & Resolution